1,489 results on '"De Koning, Harry J."'
Search Results
2. Medical costs of lung cancer by stage, histology and first-line treatment modality in the Netherlands (2012–2021)
3. Projected effectiveness of lung cancer screening and concurrent smoking cessation support in the Netherlands
4. Correction: LiverScreen project: study protocol for screening for liver fibrosis in the general population in European countries
5. Breast Cancer Screening in Georgia: Choosing the Most Optimal and Cost-Effective Strategy
6. Trade-Offs Between Harms and Benefits of Different Breast Cancer Screening Intervals Among Low-Risk Women
7. Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study
8. The Impact of Model Assumptions on Personalized Lung Cancer Screening Recommendations
9. The cost-effectiveness of different visual acuity screening strategies in three European countries: A microsimulation study
10. Early detection of obstructive coronary artery disease in the asymptomatic high-risk population: objectives and study design of the EARLY-SYNERGY trial
11. Rapid elimination of cervical cancer while maintaining the harms and benefits ratio of cervical cancer screening: a modelling study
12. LiverScreen project: study protocol for screening for liver fibrosis in the general population in European countries
13. The influence of health systems on breast, cervical and colorectal cancer screening : an overview of systematic reviews using health systems and implementation research frameworks
14. Colonoscopy-Related Mortality in a Fecal Immunochemical Test–Based Colorectal Cancer Screening Program
15. The EU-TOPIA evaluation tool: An online modelling-based tool for informing breast, cervical, and colorectal cancer screening decisions in Europe
16. Experiences, expectations and preferences regarding MRI and mammography as breast cancer screening tools in women at familial risk
17. Disability-Adjusted Life Years Averted Versus Quality-Adjusted Life Years Gained: A Model Analysis for Breast Cancer Screening
18. The optimal HPV-screening protocol in Eastern-Europe: The example of Slovenia
19. Genetic loci associated with chronic obstructive pulmonary disease overlap with loci for lung function and pulmonary fibrosis
20. Incidence of Interval Colorectal Cancer After Negative Results From First-Round Fecal Immunochemical Screening Tests, by Cutoff Value and Participant Sex and Age
21. Radiation-Induced Breast Cancer Incidence and Mortality From Digital Mammography Screening: A Modeling Study.
22. Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies.
23. Lung cancer screening in never-smokers: a balancing act
24. Systematic Review and Meta-Analysis of Community- and Choice-Based Health State Utility Values for Lung Cancer
25. The comparative effectiveness of mpMRI and MRI-guided biopsy vs regular biopsy in a population-based PSA testing: a modeling study
26. Benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts.
27. Benefits and Harms of Mammography Screening for Women With Down Syndrome: a Collaborative Modeling Study
28. Informed decision-making based on a leaflet in the context of prostate cancer screening
29. MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial
30. Results of a health systems approach to identify barriers to population-based cervical and colorectal cancer screening programmes in six European countries
31. A health systems approach to identifying barriers to breast cancer screening programmes. Methodology and application in six European countries
32. Identifying the barriers to effective breast, cervical and colorectal cancer screening in thirty one European countries using the Barriers to Effective Screening Tool (BEST)
33. Benefits, Harms, and Costs for Breast Cancer Screening After US Implementation of Digital Mammography
34. Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study
35. Cost-Effectiveness of Neonatal Hearing Screening Programs: A Micro-Simulation Modeling Analysis
36. High-pitch versus sequential mode for coronary calcium in individuals with a high heart rate: Potential for dose reduction
37. Cost-effectiveness of High-performance Biomarker Tests vs Fecal Immunochemical Test for Noninvasive Colorectal Cancer Screening
38. Coronary Artery Calcium Imaging in the ROBINSCA Trial: Rationale, Design, and Technical Background
39. Accuracy of screening women at familial risk of breast cancer without a known gene mutation: Individual patient data meta-analysis
40. Cumulative risks of false positive recall and screen‐detected breast cancer after multiple screening examinations
41. Supplementary Table S1 from Survivin Autoantibodies Are Not Elevated in Lung Cancer When Assayed Controlling for Specificity and Smoking Status
42. Supplementary Figures S1-S6 from Survivin Autoantibodies Are Not Elevated in Lung Cancer When Assayed Controlling for Specificity and Smoking Status
43. Data from Survivin Autoantibodies Are Not Elevated in Lung Cancer When Assayed Controlling for Specificity and Smoking Status
44. Modeling the natural history of ductal carcinoma in situ based on population data
45. Wise Prostate-specific Antigen Testing Means a Limited, Risk-adjusted, and Personal Approach
46. Supplementary Histology classifications from Lung Cancer Detectability by Test, Histology, Stage, and Gender: Estimates from the NLST and the PLCO Trials
47. Data from What If I Don't Treat My PSA-Detected Prostate Cancer? Answers from Three Natural History Models
48. Data from Differences in Natural History between Breast Cancers in BRCA1 and BRCA2 Mutation Carriers and Effects of MRI Screening-MRISC, MARIBS, and Canadian Studies Combined
49. Supplementary Figures 1-7 from Lung Cancer Detectability by Test, Histology, Stage, and Gender: Estimates from the NLST and the PLCO Trials
50. Data from Do Men and Women Need to Be Screened Differently with Fecal Immunochemical Testing? A Cost-Effectiveness Analysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.